Date: Dec 10, 2007 Source: PR Newswire (
click here to go to the source)
SAN DIEGO, Dec. 10 /PRNewswire/ -- ChemDiv, Inc., a leading
chemistry-driven global contract research organization, has announced today
the signing of a collaborative discovery research agreement with Siwa
Biotech Corporation, Oklahoma City, OK. Under the agreement, ChemDiv will
be initiating a high-throughput screen for small molecule inhibitors of
tyrosylprotein sulfotransferases. The collaboration provides Siwa Biotech
with access to ChemDiv's expertise in chemistry systems and lead discovery.
Financial terms of the collaboration were not disclosed.
"We are pleased that such a dynamic company as Siwa Biotech chose to
work with ChemDiv team on this research program," said Dr. Ilya Okun, Vice
President Biology and Chief Technology Officer at ChemDiv, Inc. "Over the
years we have been continuously building upon our integrated services
platform to provide our valued customers with strong and efficient support
for all of their discovery and development needs."
"We are excited to initiate this collaborative discovery project with
ChemDiv. The project has an excellent chance of success, based on ChemDiv's
excellent track record in small molecule drug discovery," said Kevin L.
Moore, M.D., President Siwa Biotech Corporation.
About ChemDiv, Inc.:
ChemDiv Inc. (Chemical Diversity) is a global chemistry-driven contract
research organization delivering discovery opportunities and services for
life science partners. ChemDiv is merging industrial and academic efforts
to bring new approaches to the treatment of life-threatening diseases.
Drawing on a long heritage in small-molecule chemistry research, a
dedicated and personal approach to collaborative research and development
as well as world class personnel and physical resources, ChemDiv provides
partners with access to Discovery outSource(TM) a full service drug
discovery offering encompassing synthetic chemistry; medicinal chemistry,
diverse & focused screening libraries, global logistics and lead discovery.
http://www.chemdiv.com
About Siwa Biotech Corporation:
Siwa Biotech Corporation is a start-up biotech company that was founded
in late 2005. The company seeks to exploit its extensive portfolio of
issued patents and proprietary knowledge about protein-tyrosine sulfation
in order to develop treatments for serious diseases. Siwa is investigating
the modulation of protein-tyrosine sulfation to treat a variety of diseases
with unmet medical needs.
